### Covidrheum

#### Adding new Unique Identifier 116

<table>
<thead>
<tr>
<th>Unique Identifier</th>
<th>116</th>
</tr>
</thead>
</table>

**Rheum COVID-19 Patient Information (part 1)**

**Unique Patient Identifier:** ______ - 1

<table>
<thead>
<tr>
<th>Provider ID * must provide value</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Unique Patient Identifier * must provide value</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Today’s date * must provide value</th>
</tr>
</thead>
</table>

**Patient age** * must provide value

19-99 years

This registry is for **adult** patients only. For the pediatric registry please go to the [pediatric registry link](#) (TK).

**Patient sex at birth** * must provide value

- Female
- Male
- Other or not known

**COVID-19 information**

**COVID-19 Diagnosis: Date** * must provide value

If day is unknown, enter 15.

**COVID-19 Diagnosis: location**

- Home or standalone testing (e.g., mobile testing site)
- Nursing home or assisted living facility
- Outpatient facility
- Emergency department
- Inpatient/hospital
- Unknown
- Other

**COVID-19 Diagnosis: How was the COVID-19 diagnosis made?**

- Presumptive diagnosis based on symptoms only
- PCR
- Antibody
- Metagenomic testing
- CT scan
- Laboratory assay, type unknown
- Unknown
- Other

Check all that apply

**Has this patient ever had symptoms of COVID-19 infection?**

- Yes
- No
- Unknown

---

https://redcap.ucsf.edu/redcap_v9.5.19/DataEntry/index.php?pid=29298&id=116&event_id=145384&page=covidrheum&auto=1
### COVID-19: Treatment

**Only include medications given as treatment for this infection. Treatment for underlying rheumatic disease listed in next section.**

- No treatment except supportive care
- Remdesivir
- Lopinavir/ritonavir
- Anti-malarials (e.g. chloroquine, hydroxychloroquine)
- IL-6 inhibitors (e.g. tocilizumab, sarilumab, siltuximab)
- Bevacizumab
- JAK inhibitors (e.g. tofacitinib, baricitinib, upadacitinib)
- Serpin inhibitors
- Ciclesonide
- Glucocorticoids
- IVIG
- Plasma from recovered patients
- Other

Check all that apply

### COVID-19: Treatment, additional notes/other:

- [ ]

### Is the patient deceased?

- [ ] Yes, deceased
- [ ] Not deceased or vital status not known at this time

**Must provide value**

### COVID-19: Complications

- No known complications
- Acute Respiratory Distress Syndrome or ARDS
- Sepsis
- Myocarditis or new heart failure
- Concomitant or secondary infection (e.g. Influenza)
- Other serious complication

Check all that apply

### Infection Acquisition: In the 14 days before onset of illness did the patient have any of the following?

- [ ] History of travel to an area with documented cases of COVID-19 infection
- [ ] Close contact with a confirmed or probable case of COVID-19 infection
- [ ] Presence in a healthcare facility where COVID-19 infections have been managed
- [ ] None of the above (community acquired)
- [ ] Unknown
- [ ] Other

Check all that apply

### Rheumatic or Autoimmune Disease and Treatment
Primary rheumatic/autoimmune diagnosis(es)

- ANCA-associated vasculitis (e.g., GPA, EGPA)
- Other vasculitis including Kawasaki disease
- Anti-phospholipid antibody syndrome
- Autoinflammatory syndrome (including TRAPS, CAPS, FMF)
- Axial spondyloarthritis (including ankylosing spondylitis)
- Other spondyloarthritis (including reactive arthritis)
- Behcet's
- Chronic recurrent multifocal osteomyelitis
- Giant cell arteritis
- IgG4-related disease
- Inflammatory myopathy (e.g. dermatomyositis, polymyositis)
- Juvenile idiopathic arthritis, not systemic
- Systemic juvenile idiopathic arthritis
- Mixed connective tissue disease
- Ocular inflammation
- Polymyalgia rheumatica
- Psoriatic arthritis
- Rheumatoid arthritis
- Other inflammatory arthritis
- Sarcoidosis
- Sjogren's syndrome
- Systemic lupus erythematosus
- Systemic sclerosis
- Undifferentiated connective tissue disease
- Other

Please check only primary diagnosis.

Rheumatic/autoimmune disease activity at the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic):

- Remission
- Minimal or low disease activity
- Moderate disease activity
- Severe or high disease activity
- Unknown

Treatments for underlying rheumatic/autoimmune disease

Glucocorticoids (including prednisone, methylprednisolone) at time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic):

- Yes
- No
- Unknown

Immune modulating medications immediately prior to the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic): Medication 1

- Stopped
- Continued
- Unknown

Was medication 1 stopped or continued after COVID-19 diagnosis?

- Stopped
- Continued
- Unknown

Immune modulating medications immediately prior to the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic): Medication 2

- Stopped
- Continued
- Unknown

Was medication 2 stopped or continued after COVID-19 diagnosis?
Immune modulating medications immediately prior to the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic): Medication 3

- Was medication 3 stopped or continued after COVID-19 diagnosis?
  - Stopped
  - Continued
  - Unknown

Immune modulating medications immediately prior to the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic): Medication 4

- Was medication 4 stopped or continued after COVID-19 diagnosis?
  - Stopped
  - Continued
  - Unknown

Immune modulating medications immediately prior to the time of COVID-19 symptom onset (or at COVID-19 diagnosis if asymptomatic): Medication 5

- Was medication 5 stopped or continued after COVID-19 diagnosis?
  - Stopped
  - Continued
  - Unknown

At the time of COVID-19 symptom onset (or diagnosis if asymptomatic), was the patient taking any of the following medications?

<table>
<thead>
<tr>
<th>Medication Type</th>
<th>Yes and medication continued</th>
<th>Yes and medication stopped</th>
<th>No</th>
<th>Unknown</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACE inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiotensin receptor blocker</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory (NSAID)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDS inhibitor (e.g., sildenafil)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Comorbidity and Pregnancy

- None
- Interstitial lung disease (e.g. NSIP, UIP, IPF)
- Obstructive lung disease (COPD/asthma)
- Other lung disease
- Diabetes
- Morbid obesity (BMI 40+)
- Hypertension
- Cardiovascular disease (coronary artery disease, congestive heart failure)
- Pulmonary hypertension
- Chronic renal insufficiency or end stage renal disease
- Cancer
- Organ transplant recipient
- Immunodeficiency
- Inflammatory bowel disease
- Liver disease
- Chronic neurological or neuromuscular disease
- Trisomy 21
- Psychiatric condition (e.g., schizophrenia, bipolar disorder)
- Pregnancy
- Post-partum (< 6 weeks)
- Unknown

Check all that apply

### COVID-19 Patient Information (part 2)

#### Race/ethnic origin

- Arab
- Black
- East Asian
- South Asian
- West Asian / Middle Eastern
- Pacific Islander
- Latin American
- White
- Native American / Aboriginal / 1st Nations
- Other
- Unknown or prefer not to answer

Check all that apply

#### Smoking Status

- Current smoker
- Former smoker
- Never smoked
- Unknown smoking status

Reset

#### Does the patient currently use e-cigarettes or vape?

- Yes
- No
- Unknown

Reset

#### Laboratory Test Results

- Are there any laboratory test results available related to this patient's COVID-19 infection?

- Yes
- No

Reset

#### Follow-up/Notes
May we contact you to get more information about the outcomes of this case?

- Yes
- No

Would you like to share any lessons or other aspects from this case?

Form Status

Complete? Incomplete ▼

Save & Exit Form
Save & Mark Survey as Complete ▼

-- Cancel --